181 related articles for article (PubMed ID: 34741723)
1. Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines.
Teng W; Chang TT; Yang HI; Peng CY; Su CW; Su TH; Hu TH; Yu ML; Yang HC; Wu JC
Hepatol Int; 2021 Dec; 15(6):1421-1430. PubMed ID: 34741723
[TBL] [Abstract][Full Text] [Related]
2. PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B.
Chun HS; Papatheodoridis GV; Lee M; Lee HA; Kim YH; Kim SH; Oh YS; Park SJ; Kim J; Lee HA; Kim HY; Kim TH; Yoon EL; Jun DW; Ahn SH; Sypsa V; Yurdaydin C; Lampertico P; Calleja JL; Janssen H; Dalekos GN; Goulis J; Berg T; Buti M; Kim SU; Kim YJ
J Hepatol; 2024 Jan; 80(1):20-30. PubMed ID: 37734683
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
[TBL] [Abstract][Full Text] [Related]
4. Liver histopathological lesions is severe in patients with normal alanine transaminase and low to moderate hepatitis B virus DNA replication.
Jiang SW; Lian X; Hu AR; Lu JL; He ZY; Shi XJ; Zhu DD; Wang ZY; Huang GC
World J Gastroenterol; 2023 Apr; 29(16):2479-2494. PubMed ID: 37179582
[TBL] [Abstract][Full Text] [Related]
5. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy.
Kim JH; Kim YD; Lee M; Jun BG; Kim TS; Suk KT; Kang SH; Kim MY; Cheon GJ; Kim DJ; Baik SK; Choi DH
J Hepatol; 2018 Nov; 69(5):1066-1073. PubMed ID: 30075230
[TBL] [Abstract][Full Text] [Related]
6. Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B.
Sohn W; Cho JY; Kim JH; Lee JI; Kim HJ; Woo MA; Jung SH; Paik YH
Clin Mol Hepatol; 2017 Jun; 23(2):170-178. PubMed ID: 28506056
[TBL] [Abstract][Full Text] [Related]
7. Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B.
Choi WM; Kim GA; Choi J; Han S; Lim YS
J Clin Invest; 2022 May; 132(10):. PubMed ID: 35358094
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.
Papatheodoridis GV; Sypsa V; Dalekos GN; Yurdaydin C; Van Boemmel F; Buti M; Calleja JL; Chi H; Goulis J; Manolakopoulos S; Loglio A; Voulgaris T; Gatselis N; Keskin O; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Idilman R; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2020 Jun; 72(6):1088-1096. PubMed ID: 31981727
[TBL] [Abstract][Full Text] [Related]
9. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
Kim GA; Lim YS; Han S; Choi J; Shim JH; Kim KM; Lee HC; Lee YS
Gut; 2018 May; 67(5):945-952. PubMed ID: 29055908
[TBL] [Abstract][Full Text] [Related]
10. Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy.
Yang HI; Yeh ML; Wong GL; Peng CY; Chen CH; Trinh HN; Cheung KS; Xie Q; Su TH; Kozuka R; Lee DH; Ogawa E; Zhao C; Ning HB; Huang R; Li J; Zhang JQ; Ide T; Xing H; Iwane S; Takahashi H; Wong C; Wong C; Lin CH; Hoang J; Le A; Henry L; Toyoda H; Ueno Y; Gane EJ; Eguchi Y; Kurosaki M; Wu C; Liu C; Shang J; Furusyo N; Enomoto M; Kao JH; Yuen MF; Yu ML; Nguyen MH
J Infect Dis; 2020 Jan; 221(3):389-399. PubMed ID: 31550363
[TBL] [Abstract][Full Text] [Related]
11. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.
Lee MH; Yang HI; Liu J; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; You SL; Wang LY; Chen CJ;
Hepatology; 2013 Aug; 58(2):546-54. PubMed ID: 23504622
[TBL] [Abstract][Full Text] [Related]
12. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B.
Hsu YC; Yip TC; Ho HJ; Wong VW; Huang YT; El-Serag HB; Lee TY; Wu MS; Lin JT; Wong GL; Wu CY
J Hepatol; 2018 Aug; 69(2):278-285. PubMed ID: 29551708
[TBL] [Abstract][Full Text] [Related]
13. Validation of the CAMD Score in Patients With Chronic Hepatitis B Virus Infection Receiving Antiviral Therapy.
Kim SU; Seo YS; Lee HA; Kim MN; Kim EH; Kim HY; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
Clin Gastroenterol Hepatol; 2020 Mar; 18(3):693-699.e1. PubMed ID: 31252188
[TBL] [Abstract][Full Text] [Related]
14. Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B.
Lee HW; Chon YE; Kim BK; Yip TC; Tse YK; Wong GL; Wong VW; Chan HL; Ahn SH
Eur J Intern Med; 2021 Feb; 84():68-73. PubMed ID: 33288393
[TBL] [Abstract][Full Text] [Related]
15. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase.
Huang DQ; Tran A; Yeh ML; Yasuda S; Tsai PC; Huang CF; Dai CY; Ogawa E; Ishigami M; Ito T; Kozuka R; Enomoto M; Suzuki T; Yoshimaru Y; Preda CM; Marin RI; Sandra I; Tran S; Quek SXZ; Khine HHTW; Itokawa N; Atsukawa M; Uojima H; Watanabe T; Takahashi H; Inoue K; Maeda M; Hoang JK; Trinh L; Barnett S; Cheung R; Lim SG; Trinh HN; Chuang WL; Tanaka Y; Toyoda H; Yu ML; Nguyen MH
Hepatology; 2023 Nov; 78(5):1558-1568. PubMed ID: 37184202
[TBL] [Abstract][Full Text] [Related]
16. External validation of hepatocellular carcinoma risk scores in patients with chronic hepatitis B virus infection in China.
Lou T; Li B; Xiong P; Jin C; Chen Y
J Viral Hepat; 2021 Oct; 28(10):1373-1380. PubMed ID: 34218498
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study.
Kim SU; Seo YS; Lee HA; Kim MN; Lee EJ; Shin HJ; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
Cancer Epidemiol Biomarkers Prev; 2020 Apr; 29(4):832-837. PubMed ID: 31988073
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of hepatocarcinoma-related hepatitis B virus mutants in patients in grey zone of treatment.
Gil-García AI; Madejón A; Francisco-Recuero I; López-López A; Villafranca E; Romero M; García A; Olveira A; Mena R; Larrubia JR; García-Samaniego J
World J Gastroenterol; 2019 Oct; 25(38):5883-5896. PubMed ID: 31636479
[TBL] [Abstract][Full Text] [Related]
19. Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis.
Hoang JK; Yang HI; Le A; Nguyen NH; Lin D; Vu VD; Chaung K; Nguyen V; Trinh HN; Li J; Zhang JQ; Chen CJ; Nguyen MH
Medicine (Baltimore); 2016 Aug; 95(31):e4433. PubMed ID: 27495067
[TBL] [Abstract][Full Text] [Related]
20. Reduction of chronic hepatitis B-related hepatocellular carcinoma with anti-viral therapy, including low risk patients.
Lin D; Yang HI; Nguyen N; Hoang J; Kim Y; Vu V; Le A; Chaung K; Nguyen V; Trinh H; Li J; Zhang J; Hsing A; Chen CJ; Nguyen MH
Aliment Pharmacol Ther; 2016 Oct; 44(8):846-55. PubMed ID: 27549411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
